Nick Bruce joins MAP Biopharma Limited to enhance market access capabilities

Paul Hudson is to succeed Olivier Brandicourt as Chief Executive Officer at Sanofi. 

MAP BioPharma enhances market access capabilities by hiring the Director of Value Access and Policy at Amgen UK- Nick Bruce joins MAP Biopharma Limited.


Nick Bruce joins MAP Biopharma Limited (MAP) after a long and distinguished career in the NHS, consultancy and the pharmaceutical industry.

In the new post, under the lead of Mark Harries as Chief Consulting Officer, he will oversee MAP’s general market access consulting offering and will work closely with the health economics & outcomes research team led by Jade Marshall. Mark, Nick and Jade collectively work alongside the policy & public affairs team led by Tessa Hughes and the market access legal support led by Angelika Gornikowska to address patient access issues holistically.

Bruce is a former NHS economist who worked for Health Authorities in South West London and at a health economics consultancy. He joined the pharmaceutical firm Pfizer in 1998 to set up its market access team and has held roles of increasing seniority responsible for market access, health policy, government affairs and media communications. He is a former ABPI representative on the Scottish Medicines Consortium appraisal committee and a former member of the ABPI Board of Management.

On Bruce joining the MAP team, CEO Christian Hill said “We are thrilled by how our MAP on-line market access service has grown, and with that, our tailored and bespoke consultancy services for our members. It is a pivotal and exciting time for MAP and we want to further nurture the creative talents we already have within the team, and bring in exceptional leadership qualities to add to our management team and Board”.

“We are therefore delighted to welcome Nick to the team. His extensive depth and breadth of industry and health technology assessment experience complements our existing team of experts, and expands our capacity to achieve our vision to become the market leader in accelerating patient access to new medicines, devices and diagnostics. We are hugely excited by the appointment”.